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1. Introduction 
Heart transplantation provides considerable survival benefits for patients with end-stage 
heart failure, but it is available for only a small fraction of these patients due to donor 
shortage. Especially in Japan, domestic legal issues had severely limited the number of heart 
transplantation until the Revised Organ Transplant Law was launched in 2010. The mean 
waiting period of Japanese heart transplant candidates after left ventricular assist device 
(LVAD) surgery had exceeded 2 years and occasionally reached 4 years until recently 
(Sasaoka T et al., 2010). 
The long-term LVAD support can result in serious complications such as cerebrovascular 
accident (CVA), the most common cause of death following LVAD surgery (Rose EA et al., 
2001; Holman WL, 2009; Saito S, et al. 2010). CVA is the leading cause of death and the 
primary reason for elimination from transplant eligibility. In addition, transplant recipients 
with a history of CVA face tremendous difficulties in being reintegrated into society, often 
for years after transplant (Nakajima I et al., 2011). 
Therefore, we investigated factors associated with CVA after LVAD surgery in Japanese 
patients, as well as we reviewed our treatment strategies for CVA and the outcome of these 
patients after developing CVA. 
2. Special circumstance surrounding transplant and LVAD issues in Japan 
Until recently, brain-death tests, conducted on the premise of organ donation, were only for 
possible donors aged over 15 with formally signed donor cards indicating a willingness to 
donate his or her organs.  The cardiac donation rate per million population in Japan is only 
0.08 or less than 10 cases in the nation, whereas it is 7.3 in the United States, 5.3 in Spain, and 
0.97 in South Korea in 2007 (Fukushima N et al., 2009; Hashimoto S et al., 2011). 
Furthermore, only one pulsatile extracorporeal left ventricular assist device (LVAD) 
(Toyobo-LVAS®, Nipro Corp., Tokyo, Japan, Figure 1) was covered by the National Health 
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Fig. 1. (a) Outline of the Toyobo-LVAS® system with device console (left lower panel), 
blood pumps and inflow/ outflow cannula (middle lower panel) and the chart of the LVAD 
system (right lower panel). The blood pump consisted of a diaphragm with a pulsatile flow 
through two mechanical valves, operated by a pneumatically driven system. The maximum 
stroke volume was 70 mL per beat when testing with water. The blood contacting surface is 
covered by segmented polyurethane approved for medical use. (b) Representative pictures 
of the blood pump with mobile thrombi (upper panel) and a granulating wound at the 
penetration sites of the inflow/ outflow cannula in the abdominal skin 
Insurance System as of November 2010 (Sasaoka T et al., 2010). Some implantable LVAD 
were used for Japanese patients for the purpose of clinical trail, or when medical expense 
was paid individually. Therefore, as improbable as it may sound, Japanese patients with 
advanced heart failure were being maintained mainly by pulsatile extracorporeal Toyobo-
LVAS® as a “bridge-to-transplant”  treatment for 2 to 4 years until being transplanted. 
Needless to say, some of them died while on the device. Given these circumstances, our 
long-term management skills for overcoming LVAD–related complications have improved 
over time, with the 1-year survival now being 82% (Sasaoka T et al., 2010).  However, even 
with this success rate of survival, CVA still remains the leading cause of death.  
The Toyobo-LVAS® was actually designed for “short-term” support, but the lack of 
alternatives resulted in it becoming a “ long-term” support device in Japan. The Toyobo-
LVAS® also requires an intensive anti-coagulation therapy, such as a target prothrombin 
time-international normalized ratio of 3.0-4.0. The 3-month and 1-year CVA-free survival 
rate for a patient with Toyobo-LVAS® is 56.1% and 36.8%, respectively (Sasaoka T et al., 
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2010; Nakajima et al., 2011). The overall incidence of CVA for Toyobo-LVAS® patients was 
reported as 57.3 % at a mean observation period of 224 days, and a report from another 
institution indicated a CVA incidence of 53.6% at a mean of 505 days (Nakajima et al., 2011; 
Saito et al., 2009).  
In spite of such a high frequency of CVA development after Toyobo-LVAS® surgery, we 
could achieve a reasonably high survival rate after the device placement thanks to the use of 
prothrombin complex concentrate (PCC) for rapid reversal of warfarin-induced 
anticoagulation in this population (Takahashi A et al., 2010). We here describe (i) factors 
associated with CVA after LVAD surgery in Japanese patients in order to distinguish 
patients with high risks for CVA, and (ii) the effects of PCC for rapid reversal of warfarin-
induced anticoagulation in patients developing hemorrhagic stroke who were supported by 
LVAD, based on our experience. 
3. Pre- and post-operative risk factors associated with CVA developments in 
Japanese patients supported by left ventricular assist device  
3.1 Risk factors for CVA at any time after LVAD surgery 
Nakajima et al. reviewed a total of 118 adult Japanese patients who were supported by 
LVAD between 1994 and 2009 (Nakajima et al., 2011). A CVA was defined as an ischemic or 
hemorrhagic intracranial event that persisted beyond 24 hours or less than 24 hours with 
infarction on an image study, based on the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) adverse events definitions of stroke. Clinical 
characteristics, hemodynamic data, and laboratory indexes associated with CVA after LVAD 
surgery were analyzed.  
In total, 57 (48.3%) patients developed CVA 133.5±184.7 days after surgery. Patients who 
developed CVA revealed to have longer duration of heart failure (p=0.0039), more 
frequency of cardiomyopathy as a baseline heart disease vs myocarditis/ acute coronary 
syndrome (p=0.039), more frequency of undergoing surgery with inflow cannula site at the 
left atrium (p=0.011), and longer duration of inotropic requirement after surgery (p<0.0001) 
than those who did not develop CVA. In addition, patients with CVA had higher pre-LVAD 
mean right atrial pressure (mRA) (p=0.001), higher pre-LVAD total bilirubin (T-Bil) 
concentration (p=0.024), lower lymphocyte subset percentage (p=0.019), lower pre-LVAD 
total protein (TP) concentration (p=0.001) and larger pre-LVAD right ventricular end-
diastolic dimension (RVEDD) on echocardiogram (p=0.0003). This combination could 
discriminate patients developing CVA from those not developing CVA at any time after 
surgery with a predictive accuracy of 71.8%, which the following formula;  
z=-0.507566 + (1.5664× [baseline heart disease; 1=cardiomyopathy, 0=other diseases]) + 
(3.49143× [type of LVAD; 1=left atrium drainage Toyobo®, 0=other type of LVAD] + 
(0.123626×mRA) + (0.185355×T-Bil) - (1.04891×TP) + (0.153542×RVEDD). 
where Z > 0 indicates patients developing CVA and Z < 0 indicates patients not developing 
CVA after LVAD surgery.  
The above finding could be implicated that patients with longstanding heart failure 
associated with malnutrition as well as accompanied right heart failure would be at higher 
risk for CVA development after LVAD surgery. 
Hierarchical multiple regression analysis for the interactions between CVA associated factors 
revealed that duration of heart failure and pre-LVAD lymphocyte subset influenced the 
duration of inotropic support after surgery, which in turn influenced CVA development. 
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Accordingly, both duration of heart failure and lymphocyte subset before surgery were 
indirectly associated with CVA. In addition, right ventricular size had an effect on the duration 
of inotropic support in addition to its direct effect on CVA development (Figure 2a). 
 
 
Fig. 2. (a) A path diagram based on the hierarchical multiple regression analysis for all 
studied patients. Observed variables are delineated by squares. Unidirectional arrows 
indicate cause-and-effect relationships. The number next to each arrow indicates the path 
coefficient of the standard partial regression coefficient. The regression error is added 
without delineation. (b)The path diagram based on the hierarchical multiple regression 
analysis for patients survived longer than 3 months without CVA. Observed variables are 
delineated by squares. Unidirectional arrows indicate cause-and-effect relationships. 
Bidirectional arrows indicate reciprocal cause-and-effect relationships. The number next to 
each arrow indicates the path coefficient of the standard partial regression coefficient. The 
regression error is added without delineation. (Adopted from Nakajima et al. Circ J) 
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3.2 Risk factors for CVA in a chronic phase after LVAD surgery 
Because of the long waiting period supported by LVAD for transplant such as beyond 2 
years in Japan, a certain amount of patients develop CVA in a chronic phase after LVAD 
surgery. Therefore, Nakajima et al. also performed the analysis to find factors associated 
with CVA in the chronic phase after surgery by excluding patients who had CVA in an 
acute phase or who had died within 3 months after surgery. 
For this sub-analysis, duration of heart failure was longer (p=0.012), myocardial fibrosis was 
severer (p=0.034), duration of post-LVAD inotropic requirement was longer (p<0.0001), 
mRA was higher (p=0.0005), the pre-LVAD lymphocyte subset of peripheral blood was 
lower (p=0.008), and pre-LVAD RVEDD was larger (p=0.0006) in patients with CVA later 
than 3 months from the surgery compared to those who never developed CVA after 
surgery. In addition, the proportion of patients who had positive blood cultures was higher 
(p=0.0002) in patients who developed CVA in a chronic phase. The post-LVAD serum 
creatinine concentration (p=0.011) and C-reactive protein level (CRP) (p<0.0001) were higher 
in patients who developed CVA in a chronic phase than who never developed CVA after 
surgery. 
A discriminant function test revealed that a discriminant score (Z) defined using the 
following equation yielded the discriminant probability of 85.9 %: 
z=-10.0754 + (0.212146× mRA) + (0.179936× RVEDd) + (2.03552× [blood culture positivity 
after surgery; 1=positive, 0=negative]) + (0. 787837×CRP) 
where Z > 0 indicates 3 months survivors after LVAD surgery developing CVA 
subsequently and Z < 0 indicates patients would never develop CVA.  
The hierarchical analysis for evaluating interactions of factors associated with chronic phase 
CVA again revealed that both duration of heart failure and lymphocyte subset before 
surgery were indirectly associated with CVA through their effect on duration of inotropic 
support after surgery (Figure 2b). Here again, patients with longstanding heart failure 
associated with accompanied right heart failure and those with post-operative infection 
would be at higher risk for developing CVA in a chronic phase after LVAD surgery. 
Multivariate regression analysis for CVA at any time after surgery and CVA in a chronic 
phase after surgery were shown in Table 1. 
Although the population of the above study was different from heart failure patients in the 
US or European countries, the combination of pre-LVAD right heart failure and post-LVAD 
infection contribute to chronic phase CVA after surgery is worthwhile information. 
4. Prothrombin complex concentrate for rapid reversal of warfarin-induced 
anticoagulation in patients with hemorrhagic stroke supported by left 
ventricular assist device 
4.1 Prothrombin complex concentrate 
Development of hemorrhagic stroke is one of the most serious complications in patients 
supported by LVAD, who require extensive oral anticoagulant therapy (Leitz K et al. , 2007). 
Hemorrhagic stroke associated with anticoagulation has a high mortality, and more than 
50% of patients die within 30 days (Sjöblom L et al., 2001). Thus, warfarin-related 
hemorrhagic stroke is considered a medical emergency especially for patients supported by 
LVAD. Nevertheless, there are no guidelines for reversal of anticoagulation for such 
patients.  
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Parameter OR (95% CI) Discriminant score 
(95% CI) 
p value 
Associated factors for overall CVA development at any time after surgery 
cardiomyopathy  4.79 (1.31-17.4) 1.56 (0.28-2.86) 0.018 
left atrium drainage Toyobo® 32.8 (8.39-128.4) 3.49 (2.12-4.86) <0.0001 
Mean RA before surgery (mmHg) 1.13 (1.04-1.23) 0.12 (0.04-0.21) 0.005 
T-Bil before surgery (mg/ dL) 1.20 (0.95-1.52) 0.18 (-0.05-0.41) 0.12 
TP before surgery (mg/ dL) 0.35 (0.17-0.74) -1.05 [-1.80-(-0.30)] 0.006 
RVEDd before surgery (mm) 1.17 (1.07-1.28) 0.15(0.06-0.24) 0.001 
Associated factors for chronic phase CVA development  
Mean RA before surgery (mmHg) 1.24 (1. 07-1.42) 0.21 (0.07-0.35) 0.004 
RVEDd before surgery (mm) 1.20 (1.06-1.34) 0.18 (0.05-0.31) 0.006 
blood culture positive after surgery 7.66 (1.50-39.0) 2.04 (0.41-3.66) 0.015 
CRP after surgery (mg/ dL) 2.19 (1.47-3.25) 0.78 (0.39-1.18) 0.0002 
Table 1. Multivariate stepwise forward selection analysis of associated factors for CVA. 
(Adopted from Nakajima et al. Circ J 2011) 
The anticoagulation effect of warfarin is related to its ability to inhibit synthesis of the 
vitamin K-dependent clotting factors II, VII, IX, and X. The appropriate way to reverse the 
anticoagulation effect of warfarin depends on the clinical situation. Minor or asymptomatic 
bleeding needs a less aggressive reversal, whereas serious bleeding requires rapid reversal 
to avoid succeeding fatal events, regardless of the reason for anticoagulation. For major 
bleeding, guidelines recommend the administration of vitamin K (5 mg i.v. or oral), and/ or 
PCC (50 U/ kg), and/ or FFP (15 ml/ kg) (British Committee for Standards in Haematology. 
1998; Ansell J et al., 2001). 
However, reversing warfarin-induced anticoagulation by vitamin K is time consuming 
(Aguilar MI et al., 2007). Reversing anticoagulation with vitamin K requires 4 to 24 hours, 
then might cause a fatal situation after hemorrhagic events, and also its persistent effect may 
promote clot formation. Thus, vitamin K administration is not an adequate treatment as an 
emergent treatment to stop further bleeding for patients with intracranial haemorrhages 
supported by LVAD. 
The administration of fresh frozen plasma (FFP) requires substantial intravenous volume 
(Aguilar MI et al., 2007), which is not adequate for patients with heart failure. Prothrombin 
complex concentrate (PCC), which contains a high concentration of the vitamin K-
dependent coagulation factors II, VII, IX, and X, has been reported to be effective for rapid 
reversal of warfarin-induced anticoagulation. The PCC promotes a much more rapid 
reversal of (PT)- international normalized ratio (INR) than FFP or/ and vitamin K (Steiner T 
et al., 2006; Aguilar MI et al., 2007) which is explained by its higher concentration of 
coagulation factors than FFP. The PCC product (PPSB-HT®; Nihon Pharmaceuticals, Tokyo, 
Japan) became available at our institution since 2001, and it has been used for emergency 
reversal of warfarin-induced anticoagulation such as hemorrhagic stroke, intraabdominal 
haemorrhage and cardiac tamponade.  
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4.2 Our experience of using prothrombin complex concentrate 
Takahashi et al. reviewed 38 consecutive hemorrhagic stroke events occurred in patients 
supported by LVAD for bridge-to-transplantation between 1996 and 2007 at National 
Cerebrovascular Center, Osaka, Japan (Takahashi A et al., 2010). Fourteen hemorrhagic 
strokes were treated by FFP and 24 hemorrhagic strokes were treated by PCC. The FFP was 
initially administrated after the evens at the dosage of body weight (kg) × 0.08 × (100-
hematocrit/ 100) × 0.3 × 0.2 × 1000 (ml). If the PT-INR was still greater than 2 after the initial 
FFP administration, additional FFP was administrated. In patients who were treated with 
PCC, the initial dosage of 500 to 1000 units were administered for 30 to 60 minutes, and if 
the INR was greater than 2 after the initial PCC administration, additional PCC was 
administrated. The proportion of patients’ survival after the hemorrhagic stroke was 
significantly smaller in those treated with FFP administration than those who were treated 
with PCC (35.7% vs. 75.0%, p < 0.05). Only 18% of patients who were treated with FFP could 
be back on the transplant waiting list, while 58% of patients treated with PCC could be back 
on the waiting list. None of the patients who were only treated with FFP and not received 
PCC were able to undergo heart transplantation, whereas 21.4% patients who were treated 
with PCC successfully underwent heart transplantation. 
Representative computed tomography scans from a patient treated with FFP and a patients 
receiving PCC were shown in Figure 3. 
Several studies demonstrated the effect of recombinant activated factor VII on warfarin 
reversal and reported successful results treating hemorrhagic stroke events (Deveras RAE et 
al., 2002). Further studies are required to establish the difference of the effect of warfarin 
reversal between PCCs and recombinant activated factor VII. 
5. Conclusion 
Patients’ general condition including malnutrition, in addition to device selection, would 
contribute to overall CVA development after surgery. In the chronic phase after surgery, 
pre-LVAD right heart failure and post-LVAD systemic infection were highly associated with 
CVA development. It was noteworthy that post-operative infection was selected as 
discriminating factors for CVA development in a chronic phase. An association of right 
heart dysfunction with a high mortality rate after LVAD surgery has been reported, 
although the association between pre-LVAD right heart failure and post-LVAD CVA was 
not fully evaluated. The longstanding heart failure might cause not only biventricular 
failure but also systemic vascular dysfunction including cerebral blood vessel. In addition, 
patients with biventricular failure required a long duration of inotropic support after LVAD. 
Long-term inotropic dependency due to right heart failure might cause line infections 
leading to systemic infection.  
This unique situation surrounding LVAD issues in Japan may have influenced the results of 
this study, especially with respect to early postoperative outcome. The number of patients 
on devices as a ‘destination therapy’ has been increasing worldwide. Even in the era of new 
generation devices, CVA remains to be important complication. In that sense, we believe 
that the information described in this chapter are helpful in the long-term management 
strategies from the perspective of CVA risk stratification in patients on destination therapy 
devices. 
Administration of PCC can result in a prompt reversal of warfarin-induced anticoagulation, 
and could be of importance for the survival of patients supported by LVAD, who require 
intensified anticoagulation therapy and who are at high risk for hemorrhagic stroke. 
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Fig. 3. Representative images of computed tomography head scan from patients in Group 
FFP (a) and in Group PCC (b). (a) A 50-year-old male developed ICH in the right frontal 
lobe with a PT-INR of 3.61. After 4160 ml of FFP administration resulting in PT-INR of 1.73, 
the patients required neurosurgery. Due to residual ICH, the patient required additional 
neurosurgery but eventually died. (b) A 41-year-old female developed ICH in the right 
posterior lobe with a PT-INR of 3.47. The immediate administration of 1000 units of PCC 
resulted in the PT-INR of 1.21 within 20 minutes. The patient underwent heart 
transplantation 2.8 years after the ICH event without neurological after-effects 
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